I’ll let you in on a little secret: I’m not supposed to attend the health care conference in Boston organized by the investment bank Cowen each March. Technically, it’s a media-free event.
But as long as I behave myself and don’t live-tweet from the sessions, Cowen tolerates my presence. I’m grateful because the conference’s unique setup — investors and doctor-specialists critique approved and experimental drugs across nearly two dozen disease areas — offers a helpful sentiment check on biotech and pharma companies.
Here’s some of what I heard and learned at this week’s Cowen conference:
About the Author Reprints
Can I switch my email address to [email protected]